News Kisqali set for approval - but likely to hit same NICE obsta... Concerns that NICE will reject Kisqali like it did Ibrance.
Views & Analysis Will UK patients get access to novel drugs? Access to new medicines is not high up the list of priorities for NHS England, but pharma must seize opportunities to promote innovation uptake.
News Kadcyla finally gets OK after price cut and NICE concessions Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE.
News Amgen’s myeloma treatment Kyprolis gains NICE approval NICE has recommended Amgen’s multiple myeloma treatment Kyprolis, a next generation drug which has shown itself superior to Janssen’s standard treatment Velcade.
News Lilly’s sarcoma drug Lartruvo recommended via Cancer Drugs F... Lilly's drug will be re-appraised in 2020
News SCOTUS backs generic firm Hikma in skinny label dispute SCOTUS has delivered its ruling in a closely watched 'skinny label' lawsuit between Amarin and Hikma, which could have far-reaching implications.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
